Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy
Protein Degradation Specialist Gets $1bn Up Front
Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.
You may also be interested in...
The frontrunner in the new protein degrader class has shown lackluster Phase II results in breast cancer, but Arvinas hopes for success in less heavily pre-treated patients in Phase III.
Kymera has seen its share price fall more than 30% this week as investors struggle to gauge how much future market potential targeted protein degraders will have.
It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.